Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

Tardif et al. (Fri,) studied this question.

www.synapsesocial.com/papers/69cdfe8c3d84e1f5ff46c480 — DOI: https://doi.org/10.1093/eurheartj/ehab820

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus· 2010 · 2,842 citations
2. Clinical review on triglycerides· 2019 · 535 citations
3. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia· 2020 · 275 citations
4. VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins· 2020 · 180 citations
5. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial· 2018 · 195 citations